CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 173 filers reported holding CLOVIS ONCOLOGY INC in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $89,000 | -62.8% | 49,400 | -58.3% | 0.00% | -100.0% |
| Q1 2022 | $239,000 | -60.8% | 118,500 | -47.3% | 0.00% | -50.0% |
| Q4 2021 | $609,000 | +107.1% | 224,900 | +241.3% | 0.00% | +100.0% |
| Q3 2021 | $294,000 | +83.8% | 65,900 | +162.5% | 0.00% | 0.0% |
| Q1 2020 | $160,000 | -94.5% | 25,100 | -96.6% | 0.00% | -85.7% |
| Q3 2019 | $2,923,000 | +243.1% | 743,706 | +1197.8% | 0.01% | +250.0% |
| Q2 2019 | $852,000 | +54.6% | 57,306 | +158.1% | 0.00% | +100.0% |
| Q1 2019 | $551,000 | -83.3% | 22,200 | -54.1% | 0.00% | -88.9% |
| Q4 2017 | $3,291,000 | +648.0% | 48,400 | +929.8% | 0.01% | +800.0% |
| Q2 2017 | $440,000 | -50.3% | 4,700 | -66.2% | 0.00% | -66.7% |
| Q1 2017 | $885,000 | -8.4% | 13,900 | -49.6% | 0.00% | -50.0% |
| Q4 2015 | $966,000 | +0.9% | 27,601 | +165.2% | 0.01% | 0.0% |
| Q3 2015 | $957,000 | +80.6% | 10,406 | -18.7% | 0.01% | +50.0% |
| Q2 2014 | $530,000 | – | 12,806 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |